Dateline: November 14, 2025 — Mumbai, India / Baltimore, Maryland
Lupin has launched its Risperidone Long-Acting Injectable (LAI) in the United States with 180-day Competitive Generic Therapy (CGT) exclusivity, marking the first commercial product from its proprietary PrecisionSphere™ long-acting injectable platform. This milestone strengthens Lupin’s entry into the complex-injectables segment and expands patient access to a critical therapy used in managing schizophrenia and bipolar disorder, while showcasing the company’s technological and regulatory capabilities in advanced drug-delivery systems.
Science Significance
The launch of Risperidone LAI represents a significant scientific advance for Lupin, built on its PrecisionSphere™ microsphere-based delivery technology, designed to provide sustained and predictable drug release over multiple weeks. By engineering precise particle uniformity and controlled polymer-matrix behavior, the platform enhances dose consistency and reduces variability in therapeutic exposure. This innovation not only demonstrates Lupin’s scientific progress in polymer-based extended-release formulations but also expands the scientific landscape for long-acting antipsychotic therapeutics, which require stability, sterility, and performance across multiple injection intervals. As the first product from this platform, Risperidone LAI establishes a foundation for future LAI developments targeting CNS and chronic-disease conditions.
Regulatory Significance
The product received U.S. FDA approval under the ANDA pathway, accompanied by 180-day CGT exclusivity, underscoring its regulatory importance. This exclusivity period highlights Lupin’s success in meeting strict quality, bioequivalence and manufacturing criteria for a complex parenteral formulation—a recognized challenge for injectable generics. PrecisionSphere-based manufacturing required Lupin to demonstrate robust GMP compliance, particulate integrity, aseptic controls, and sustained-release equivalence compared with the reference listed drug. The approval reinforces the FDA’s ongoing commitment to expanding competition in markets with limited generic options while rewarding manufacturers who invest in technologically demanding drug-delivery platforms.
Business Significance
Advertisement
Commercially, this launch positions Lupin as a serious contender in the high-value complex generics and LAI markets, which have significant entry barriers due to manufacturing intricacies and regulatory demands. The 180-day exclusivity window provides a competitive advantage, allowing Lupin to secure early market share in the U.S. antipsychotic injectables segment—a category with strong demand due to rising adoption of long-acting therapies that reduce relapse risk. Additionally, the product serves as the commercial proof-point for the PrecisionSphere™ platform, enhancing Lupin’s portfolio differentiation and strengthening its strategic position with payers, healthcare providers and global partners seeking reliable LAI manufacturing capabilities
Patients’ Significance
For patients living with schizophrenia or bipolar disorder, long-acting injectables offer improved treatment adherence, reduced relapse risk and more stable therapeutic outcomes. The availability of Lupin’s Risperidone LAI provides a more accessible and potentially more affordable option, particularly during the exclusivity period when generic competition remains limited. The product’s controlled-release features are designed to maintain steady plasma levels, reducing the fluctuations often observed with oral dosing and offering clinical teams additional confidence in maintaining consistent disease management. Expanded access to LAI formulations is especially impactful for patients with adherence challenges, enhancing long-term treatment continuity and stability.
Policy Significance
From a policy perspective, the launch exemplifies the success of the Competitive Generic Therapy (CGT) program, which aims to stimulate competition in markets with insufficient generic availability. The FDA’s decision to grant exclusivity reflects the policy priority of addressing drug-access gaps—especially in critical therapeutic areas such as mental health. It also reinforces the importance of supporting manufacturers capable of producing complex injectables, a domain where regulatory incentives and manufacturing innovation intersect to expand patient access. The product aligns with national priorities emphasizing mental-health treatment accessibility and improved outcomes through long-acting therapeutic modalities.
Lupin’s introduction of Risperidone Long-Acting Injectable to the U.S. market with CGT exclusivity marks a defining moment for the company’s evolution into advanced injectable technologies. Backed by its PrecisionSphere™ platform, the launch advances scientific innovation, regulatory achievement and business growth while directly benefitting patients and strengthening broader health-policy objectives. As Lupin continues to expand its LAI pipeline, this milestone establishes a strong precedent for future complex-injectable developments in the global pharmaceutical landscape.
Source: Lupin Limited press release
